Latest Conference Articles

Anabela Cardoso, MD, discussed lebrikizumab’s efficacy in improving itch, skin pain, sleep disturbance, and long-term management in atopic dermatitis.

Efficacy, safety, and pharmacokinetic data support the use of vilobelimab in treating pyoderma gangrenosum and hidradenitis suppurativa.

Johnson & Johnson’s JNJ-2113 showed promise for PsO, achieving high skin clearance with a strong safety profile.

Catch up on coverage from the fourth day of the 2025 American Academy of Dermatology Annual Meeting held in Orlando, Florida.

At AAD 2025, Karan Lal, DO, MS, FAAD, presented clinical insights on insulated microneedling tips, grounding pad issues in monopolar radiofrequency, and more.

Gold discussed breakthrough treatments for scars, including silicone, energy-based devices, and radiation therapy.

Christopher Bunick, MD, PhD, explains what comes next for clinicians and patients live at AAD 2025.

Stark highlighted Bimzelx’s role in treating psoriasis and HS, introduced the BE BOLD study for PsA, and looked to future innovation in inflammatory skin disease.

Lio shared insights on minimizing pain in dermatologic procedures, highlighting practical techniques from his AAD 2025 presentations.

Catch up on coverage from the third day of the 2025 American Academy of Dermatology Annual Meeting held in Orlando, Florida.

Gold emphasized the necessity of recognizing and managing complications in aesthetic dermatology to ensure patient safety and optimal outcomes.

AbbVie’s phase 2 study demonstrates how upadacitinib reduces type 1 inflammation and boosts melanocyte biomarkers to drive vitiligo response.

Findings suggest that most patients on risankizumab met or exceeded the National Psoriasis Foundation’s treatment goals.

Adamson dives deep into artificial intelligence, molecular testing, and melanoma overdiagnosis.

At AAD 2025, Raj Chovatiya, MD, PhD, MSCI, explored the role of social determinants in AD, HS, and PsO, emphasizing the need for improved clinical recognition and inclusive research.

Anabela Cardoso, MD, provides data on the phase 3 BRAVE-AA-PEDS trial, the largest JAK inhibitor study dedicated to adolescents with severe alopecia areata, at AAD.

Catch up on coverage from the second day of the 2025 American Academy of Dermatology Annual Meeting held in Orlando, Florida.

April Armstrong, MD, MPH, FAAD, discusses her late-breaking presentation at AAD on the treatment response in patients with moderate to severe chronic CHE treated with delgocitinib.

Michael Sherling, MD, MBA, leverages AI to simplify administrative tasks and focus on patient care.

Adamson highlighted melanoma's rising incidence and the growing concerns of overdiagnosis at AAD 2025.

Shawn Kwatra, MD, FAAD, reviews his late-breaking data presentation at AAD on the first original studies of a topical cream for prurigo nodularis.

Linda Stein Gold, MD, FAAD, discusses the late-breaking tapinarof cream data presented at AAD 2025.

The ADORING 3 study demonstrated that tapinarof cream 1% maintains low disease activity in patients with AD for an average of 79.8 days post-treatment.

At AAD 2025, UCB will present 5-year data for Bimzelx in psoriasis, highlighting rapid, durable responses and long-term safety for patients.

Charrow shares insights in complex dermatology and her work in HS at the annual meeting.

Catch up on coverage from the first day of the 2025 American Academy of Dermatology Annual Meeting held in Orlando, Florida.

Raj Chovatiya, MD, PhD, MSCI, discusses how early-career dermatologists can gain the most benefit from this year’s annual meeting.

Jeanine Downie, MD, FAAD, discussed critical updates on tattoo ink safety, new dermatologic technologies, biostimulators, and more at AAD 2025.